Abstract
Mitral and tricuspid valve regurgitation remain among the most prevalent valvular defects. The treatment strategy critically depends on the etiology of disease and differs with respect to the role of medical therapy, the timing of intervention, the strategy of whether to replace or repair, and the use of a transcatheter approach. Here, we summarize currently approved transcatheter therapies for the treatment of mitral and tricuspid regurgitation. Given the prevalence of disease and the high and increasing number of transcatheter procedures in particular for mitral valve regurgitation, the German Cardiac Society herewith publishes criteria for centers for transcatheter mitral valve therapy.
Item Type: | Journal article |
---|---|
Faculties: | Medicine |
Subjects: | 600 Technology > 610 Medicine and health |
ISSN: | 1864-9718 |
Language: | German |
Item ID: | 64848 |
Date Deposited: | 19. Jul 2019, 12:16 |
Last Modified: | 04. Nov 2020, 13:44 |